2427667-03-4
Chemical Structure
Quisovalimab
Synonym(s): AVTX-002; AEVI 002; SAR 252067; CERC-002; MDGN-002
- CAS No.: 2427667-03-4
- Formula:N/A
- Molecular Weight:(144.32 kDa)
IUPAC Name: N-(2-fluoro-4-((1S,2S)-2-(pyridin-3-yl)cyclopropane-1-carboxamido)benzyl)-4-(piperazin-1-yl)benzamide trihydrochloride
SMILES: [Quisovalimab]
Biological Activity: Quisovalimab (AVTX-002) is a human-derived monoclonal antibody against LIGHT (TNFSF14). Quisovalimab binds to LIGHT, blocks the signal transduction activity of LIGHT, reduces circulating LIGHT levels and attenuates pro-inflammatory effects. Quisovalimab can be used in research related to Crohn's disease, COVID-19-associated pneumonia and acute respiratory distress syndrome comorbidity[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Quisovalimab | 99.08% | Quisovalimab (AVTX-002) is a human-derived monoclonal antibody against LIGHT (TNFSF14). Quisovalimab binds to LIGHT, blocks the signal transduction activity of LIGHT, reduces circulating LIGHT levels and attenuates pro-inflammatory effects. Quisovalimab can be used in research related to Crohn's disease, COVID-19-associated pneumonia and acute respiratory distress syndrome comorbidity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Mousa RS, et al. TNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD. Front Immunol. 2025;16:1657071. Published 2025 Sep 15. [Content Brief]
- [2]. Ware CF, et al. Realigning the LIGHT signaling network to control dysregulated inflammation. J Exp Med. 2022;219(7):e20220236. [Content Brief]
- [3]. Perlin DS, et al. Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS. mSphere. 2020;5(4):e00699-20. Published 2020 Aug 12. [Content Brief]
